Sticking it to scleroderma: Potential therapies blocking elevated adhesive and contractile signaling

Current Enzyme Inhibition

Volumn 6, Issue 2, 2010, Pages 97-104

  Leask, Andrew ^a  

^a WESTERN UNIVERSITY   (Canada)

Author keywords

Endothelin; PDGF; PKC ; PPAR ; Rac; TGF

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ANTIFIBROTIC AGENT; CONNECTIVE TISSUE GROWTH FACTOR; DASATINIB; ENDOTHELIN 1; ENDOTHELIN 2; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; FOCAL ADHESION KINASE 1; IMATINIB; NILOTINIB; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR AA; PLATELET DERIVED GROWTH FACTOR AB; PLATELET DERIVED GROWTH FACTOR BB; RAC1 PROTEIN; ROSIGLITAZONE; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD4 PROTEIN; SYNDECAN 4; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1;

ARTICLE; CELL ADHESION; CELL DIFFERENTIATION; FIBROGENESIS; FIBROSIS; GENE EXPRESSION; HUMAN; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SCLERODERMA; SIGNAL TRANSDUCTION;

EID: 82155194849     PISSN: 15734080     EISSN: 18756662     Source Type: Journal    
DOI: 10.2174/157340810791232999     Document Type: Article

References (89)

1. Eckes, B.; Zigrino, P.; Kessler, D.; Holtkotter, O.; Shephard, P.; Mauch, C.; Krieg, T. Fibroblast-matrix interactions in wound healing and fibrosis. Matrix Biol., 2000, 19, 325-332.
2. Gabbiani, G. The myofibroblast in wound healing and fibrocontractive diseases. J. Pathol., 2003, 200, 500-503.
3. Chen, Y.; Shiwen, X.; van Beek, J.; Kennedy, L.; McLeod, M.; Renzoni, E.A.; Bou-Gharios, G.; Wilcox-Adelman, S.; Goetinck, P.F.; Eastwood, M.; Black, C.M.; Abraham, D.J.; Leask, A. Matrix contraction by dermal fibroblasts requires TGFbeta/ALK5, heparan sulfate containing proteoglycans and MEK/ERK: Insights into pathological scarring in chronic fibrotic disease. Am. J. Pathol., 2005, 167, 1699-1711.
4. Hinz, B.; Phan, S.H.; Thannickal, V.J.; Galli, A.; Bochaton-Piallat, M.L.; Gabbiani, G. The myofibroblast: one function, multiple origins. Am. J. Pathol., 2007, 170, 1807-1816
5. Abraham, D.J.; Eckes, B.; Rajkumar, V.; Krieg, T. New developments in fibroblast and myofibroblast biology: implications for fibrosis and scleroderma. Curr. Rheumatol. Rep. 2007, 9, 136-143.
6. Leask, A.; Abraham, D.J. TGF-beta signaling and the fibrotic response. FASEB J., 2004, 18, 816-827
7. Roberts, A.B. TGF-beta signaling from receptors to the nucleus Microbes Infect. 1999, 1,1265-1273
8. Leask, A. Targeting the TGF β, endothelin-1 and CCN2 axis to combat fibrosis in scleroderma. Cell Signal., 2008, 20, 1409-1414.
9. Blom, I.E.; Goldschmeding, R.; Leask, A. Gene regulation of connective tissue growth factor: new targets for antifibrotic therapy? Matrix Biol. 2002, 21, 473-482.
10. Shi-wen, X.; Rodrigues-Pascual, F.; Lamas, S.; Holmes, A.; Howat, S.; Pearson, J.D.; Dashwood, M.R.; du Bois, R.M.; Denton, C.P.; Black, C.M.; Abraham, D.J.; Leask, A. Constitutive ALK5- indepenent JNK activation contributes to endothelin-1 overexpression in pulmonary fibrosis. Mol. Cell Biol., 2006, 26, 5518-5527.
11. Shi-wen, X.; Renzoni, E.A.; Kennedy, L.; Howat, S.; Chen, Y.; Pearson, J.D.; Bou-Gharios, G.; Dashwood, M.R.; du Bois, R.M.; Black, C.M.; Denton, C.P.; Abraham, D.J.; Leask, A. Endogenous endothelin-1 signaling contributes to type I collagen and CCN2 overexpression in fibrotic fibroblasts. Matrix Biol., 2007, 26, 625-632.
12. Santander, C.; Brandan, E. Betaglycan induces TGF-beta signaling in a ligand-independent manner, through activation of the p38 pathway. Cell. Signal., 2006, 18, 1482-1491.
13. Liu, S.; Shi-wen, X.; Kennedy, L.; Pala, D.; Carter, D.E.; Black, C.M.; Abraham, D.J.; Leask, A. FAK is required for TGF β -induced JNK phosphorylation in fibroblasts: implications for acquisition of a matrix remodeling phenotype. Mol. Biol. Cell., 2007, 18, 2169-2178.
14. Shi-wen, X.; Parapuram, S.K.; Pala, D.; Chen, Y.; Carter, D.; Eastwood, M.; Abraham, D.J.; Leask, A. TGFαβ̃induced α-smooth muscle actin expression and extracellular matrix contraction in fibroblasts requires TAK1. Arthritis Rheum., 2009, 60, 234-41.
15. Shi-wen, X.; Stanton, L.; Kennedy, L.; Pala, D.; Chen, Y.; Howat, S.L.; Renzoni, E.A.; Carter, D.E.; Bou-Gharios, G.; Stratton, R.J.; Pearson, J.D.; Beier, F.; Lyons, K.M.; Black, C.M.; Abraham, D.J.; Leask, A. CCN2 is necessary for adhesive responses to TGFß1 in embryonic fibroblasts. J. Biol. Chem., 2006, 281, 10715-10726.
16. Mori, T.; Kawara, S.; Shinozaki, M.; Hayashi, N.; Kakinuma, T.; Igarashi, A.; Takigawa, M.; Nakanishi, T.; Takehara, K. Role and interaction of connective tissue growth factor with transforming growth factor-beta in persistent fibrosis: a mouse fibrosis model. J. Cell Physiol., 1999, 181,153-159.
17. Ghosh, A.K.; Varga, J. The transcriptional coactivator and acetyltransferase p300 in fibroblast biology and fibrosis. J. Cell Physiol., 2007, 213, 663-671.
18. Leask, A.; Holmes, A.; Black, C.M.; Abraham, D.J. Connective tissue growth factor gene regulation. Requirements for its induction by transforming growth factor-beta 2 in fibroblasts. J. Biol. Chem., 2003, 278, 13008-13015.
19. Chen, Y.; Shi-wen, X.; Eastwood, M.; Black, C.M.; Denton, C.P.; Leask, A.; Abraham, D.J. Contribution of activin receptor-like kinase 5 (transforming growth factor beta receptor type I) signaling to the fibrotic phenotype of scleroderma fibroblasts. Arthritis Rheum., 2006, 54, 1309-1316.
20. Holmes, A.; Abraham, D.J.; Sa, S.; Shiwen, X.; Black, C.M.; Leask, A. CTGF and SMADs, maintenance of scleroderma phenotype is independent of SMAD signaling. J. Biol. Chem., 2001, 276, 10594-10601.
21. Chen, Y.; Leask, A.; Abraham, D.J.; Pala, D.; Shiwen, X.; Khan, K.; Liu, S.; Carter D.E.; Wilcox-Adelman, S.; Goetinck, P.; Denton, C.P.; Black, C.M.; Pitsillides, A.A.; Sarraf, C.E.; Eastwood, M. Heparan sulfate-dependent ERK activation contributes to the overexpression of fibrotic proteins and enhanced contraction by scleroderma fibroblasts. Arthritis Rheum., 2008, 58, 577-585
22. Leask, A.; Abraham, D.J.; Finlay, D.R.; Holmes, A.; Pennington, D.; Shi-Wen, X.; Chen, Y.; Venstrom, K.; Dou, X.; Ponticos, M.; Black, C.; Bernabeu, C.; Jackman, J.K.; Findell, P.R.; Connolly, M.K. Dysregulation of transforming growth factor beta signaling in scleroderma: overexpression of endoglin in cutaneous scleroderma fibroblasts. Arthritis Rheum., 2002, 46,1857-1865.
23. Pannu, J.; Nakerakanti, S.; Smith, E.; ten Dijke, P.; Trojanowska, M. Transforming growth factor-beta receptor type I-dependent fibrogenic gene program is mediated via activation of Smad1 and ERK1/2 pathways. J. Biol. Chem., 2007, 282, 10405-10413.
24. Denton, C.P.; Merkel, P.A.; Furst, D.E.; Khanna, D.; Emery, P.; Hsu, V.M.; Silliman, N.; Streisand, J.; Powell, J.; Akesson, A.; Coppock, J.; Hoogen, F.; Herrick, A.; Mayes, M.D.; Veale, D.; Haas, J.; Ledbetter, S.; Korn, J.H.; Black, C.M.; Seibold, J.R.; Cat- 192 Study Group; Scleroderma Clinical Trials Consortium. Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebocontrolled phase I/II trial of CAT-192. Arthritis Rheum., 2007, 56, 323-333.
25. Clozel, M.; Salloukh, H. Role of endothelin in fibrosis and antifibrotic potential of bosentan. Ann. Med., 2005, 37, 2-12.
26. Teder, P.; Noble, P.M. A cytokine reborn: endothelin-1 in pulmonary inflammation and fibrosis. Am. J. Respir. Cell Mol. Biol., 2000, 23, 7-10.
27. Shi-Wen, X.; Chen, Y.; Denton, C.P.; Eastwood, M.; Renzoni, E.A.; Bou-Gharios, G.; Pearson, J.D.; Dashwood, M.; du Bois, R.M.; Black, C.M.; Leask, A.; Abraham, D.J. Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts Mol. Biol. Cell., 2004, 15, 2707-2719.
28. Shi-wen, X.; Kennedy, L.; Renzoni, E.; du Bois, R.; Denton, C.; Black, C.; Abraham, D.; Leask A. Endothelin-1 is a downstream mediator of TGF β in fibroblasts. Arthritis Rheum. 2007, 56, 4189-4194.
29. Denton, C.P.; Pope, J.E.; Peter, H.H.; Gabrielli, A.; Boonstra, A.; van den Hoogen, F.H.; Riemekasten, G.; De Vita, S.; Morganti, A.; Dölberg, M.; Berkani, O.; Guillevin, L.; TRacleer Use in PAH associated with Scleroderma and Connective Tissue Diseases (TRUST) Investigators. Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases. Ann. Rheum. Dis., 2008, 67, 1222-1228.
30. Korn, J.H.; Mayes, M.; Matucci Cerinic, M.; Rainisio, M.; Pope, J.; Hachulla, E.; Rich E.; Carpentier, P.; Molitor, J.; Seibold, J.R.; Hsu, V.; Guillevin, L.; Chatterjee, S.; Peter, H.H.; Coppock, J.; Herrick, A.; Merkel, P.A.; Simms, R.; Denton, C.P.; Furst, D.; Nguyen, N.; Gaitonde, M.; Black, C. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum., 2004, 50, 3985-3993.
31. Park, S.H.; Saleh, D.; Giaid, A.; Michel, R.P. Increased endothelin- 1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist. Am. J. Respir. Crit. Care Med. 1997, 156, 600-608.
32. Shephard, P.; Hinz, B.; Smola-Hess, S.; Meister, J.J.; Krieg, T.; Smola, H. Dissecting the roles of endothelin, TGF-beta and GMCSF on myofibroblast differentiation by keratinocytes. Thromb. Haemost., 2004, 92, 262-274.
33. Dziadzio, M.; Usinger, W.; Leask, A.; Abraham, D.; Black, C.M.; Denton, C.; Stratton, R. N-terminal connective tissue growth factor is a marker of the fibrotic phenotype in scleroderma. QJM., 2005, 98, 485-492.
34. Leask, A. Transcriptional profiling of the scleroderma fibroblast reveals a potential role for connective tissue growth factor (CTGF) in pathological fibrosis. Keio J. Med., 2004, 53, 74-77.
35. Leask, A.; Abraham, D.J. All in the CCN family. J. Cell Science., 2006, 119, 4803-4810.
36. Bonniaud, P.; Martin, G.; Margetts, P.J.; Ask, K.; Robertson, J.; Gauldie, J.; Kolb, M. Connective tissue growth factor is crucial to inducing a profibrotic environment in fibrosis-resistant BALB/c mouse lungs. Am. J. Respir. Cell. Mol. Biol., 2004, 31, 510-516.
37. Shi-wen, X.; Stanton, L.; Kennedy, L.; Pala, D.; Chen, Y.; Howat, S.L.; Renzoni, E.A.; Carter, D.E.; Bou-Gharios, G.; Stratton, R.J.; Pearson, J.D.; Beier, F.; Lyons, K.M.; Black, C.M.; Abraham, D.J.; Leask, A. CCN2 is necessary for adhesive responses to TGFß1 in embryonic fibroblasts. J. Biol. Chem., 2006, 281, 10715-10726.
38. Kennedy, L.; Liu, S.; Shi-wen, X.; Carter, D.; Lyons, K.; Black, C.M.; Abraham, D.J.; Leask, A. CCN2 is essential for fibroblast function. Exp. Cell. Res., 2007, 313, 952-964.
39. Ponticos, M.; Holmes, A.M.; Shiwen, X.; Leoni, PL.; Khan, K.; Rajkumar, V.S.; Hoyles, R.K.; Bou-Gharios, G.; Black, C.M.; Denton, C.P.; Abraham, D.J.; Leask, A.; Lindahl, G.E. Pivotal role of connective tissue growth factor in lung fibrosis: MAPKdependent transcriptional activation of type I collagen. Arthritis Rheum., 2009, 60, 2142-2155.
40. Whitfield, M.L.; Finlay, D.R.; Murray, J.I.; Troyanskaya, O.G.; Chi, J.T.; Pergamenschikov, A.; McCalmont, T.H.; Brown, P.O.; Botstein, D.; Connolly, M.K. Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc. Natl. Acad. Sci. U.S.A., 2003, 100, 12319-12324.
41. Bonner, J.C. Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev., 2004, 15, 255-273.
42. Heldin, C.H.; Westermark, B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol. Rev., 1999, 79, 1283-1316.
43. Rhee, S.; Grinnell, F. P21-activated kinase 1: convergence point in PDGF- and LPA-stimulated collagen matrix contraction by human fibroblasts. J. Cell Biol., 2006, 172, 423-432.
44. Jinnin, M.; Ihn, H.; Mimura, Y.; Asano, Y.; Yamane, K.; Tamaki, K. Regulation of fibrogenic/fibrolytic genes by platelet-derived growth factor C, a novel growth factor, in human dermal fibroblasts. J. Cell Physiol., 2005, 202, 510-517.
45. Rajkumar, V.S.; Sundberg, C.; Abraham, D.J.; Rubin, K.; Black, C.M. Activation of microvascular pericytes in autoimmune Raynaud's phenomenon and systemic sclerosis. Arthritis Rheum., 1999, 42, 930-941.
46. Rajkumar, V.S.; Shiwen, X.; Bostrom, M.; Leoni, P.; Muddle, J.; Ivarsson, M.; Gerdin, B.; Denton, C.P.; Bou-Gharios, G.; Black, C.M.; Abraham, D.J. Platelet-derived growth factor-beta receptor activation is essential for fibroblast and pericyte recruitment during cutaneous wound healing. Am. J. Pathol., 2006, 169, 2254-2265.
47. Kapoor, M.; Liu, S.; Huh, K.; Parapuram, S.; Kennedy, L.; Leask, A. Connective tissue growth factor promoter activity in normal and wounded skin. Fibrogenesis Tissue Repair, 2008, 1, 3.
48. Akhmetshina, A.; Dees, C.; Pileckyte, M.; Maurer, B.; Axmann, R.; Jüngel, A.; Zwerina, J.; Gay, S.; Schett, G.; Distler, O.; Distler, J.H. Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. FASEB J. 2008, 22, 2214-2222.
49. Sime, P.J. The antifibrogenic potential of PPARgamma ligands in pulmonary fibrosis. J. Investig. Med., 2008, 56, 534-538.
50. Bishop-Bailey, D.; Wray, J. Peroxisome proliferator-activated receptors: a critical review on endogenous pathways for ligand generation. Prostaglandins Other Lipid Mediat., 2003, 71, 1-22.
51. Burgess, H. A.; Daugherty, L. E.; Thatcher, T. H.; Lakatos, H. F.; Ray, D. M.; Redonnet, M.; Phipps, R. P.; Sime, P. J. PPARγ agonists inhibit TGF- β induced pulmonary myofibroblasts differentiation and collagen production: implications for therapy of lung fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol., 2005, 288, L1146-L1153.
52. Ghosh, A.K.; Bhattacharyya, S.; Lakos, G.; Chen, S.J.; Mori, Y.; Varga, J. Disruption of transforming growth factor beta signaling and profibrotic responses in normal skin fibroblasts by peroxisome proliferator-activated receptor gamma. Arthritis Rheum., 2004, 50, 1305-1318.
53. Kapoor, M.; McCann, M.; Liu, S.; Huh, K.; Denton, C.P.; Abraham, D.J.; Leask, A. Loss of peroxisome proliferator-activated receptor gamma in mouse fibroblasts results in increased susceptibility to bleomycin-induced skin fibrosis. Arthritis Rheum., 2009, 60, 2822-2829
54. Ghosh, A.K.; Bhattacharyya, S.; Wei, J.; Kim, S.; Barak, Y.; Mori, Y.; Varga, J. Peroxisome proliferator-activated receptor-gamma abrogates Smad-dependent collagen stimulation by targeting the p300 transcriptional coactivator. FASEB J., 2009, 23, 2968-2977.
55. Wu, M.; Melichian, D.S.; Chang, E.; Warner-Blankenship, M.; Ghosh, A.K.; Varga, J. Rosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptor-gamma. Am. J. Pathol., 2009, 174, 519-533.
56. Duan, S.Z.; Usher, M.G.; Mortensen, R.M. Peroxisome proliferator- activated receptor-γ-mediated effects in the vasculature. Circ. Res., 2008, 102, 283-294.
57. Shiwen, X.; Eastwood, M.; Stratton, R.J.; Denton, C.P.; Leask, A.; Abraham, D.J. PPARγ expression is decreased in skin scleroderma fibroblasts. Rheumatology, in press.
58. Kennedy, L.; Shi-Wen, X.; Carter, D.E.; Abraham, D.J.; Leask, A. Fibroblast adhesion results in the induction of a matrix remodeling gene expression program. Matrix Biol., 2008, 27, 274-281.
59. Sheppard, D. In vivo functions of integrins: lessons from null mutations in mice, Matrix Biol., 2000, 19, 203-209.
60. van der Flier, A.; Sonnenberg, A. Function and interactions of integrins. Cell Tissue Res., 2001, 305,285-298.
61. Schwartz, M.A. Integrin signaling revisited, Trends Cell Biol., 2001, 11, 466-470.
62. Liu, S.; Kapoor, M.; Denton, C.P.; Abraham, D.J.; Leask, A. Loss of β 1 integrin in mouse fibroblasts results in resistance to a mouse model of skin scleroderma. Arthritis Rheum., 2009, 60, 2817-2821
63. Wipff, P.J.; Hinz, B. Integrins and the activation of latent transforming growth factor beta1 - an intimate relationship. Eur. J. Cell Biol., 2008, 87, 601-615.
64. Gaoxiang, G.; Greenspan, D.S. BMP1 controls TGF{beta}1 activation via cleavage of latent TGF{beta}-binding protein, J. Cell Biol., 2006, 175, 111-120.
65. Yu, Q.; Stamenkovic, I. Cell surface-localized matrix metalloproteinase- 9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis, Genes Dev., 2000, 14, 163-176.
66. Lyons, R.M.; Gentry, L.E.; Purchiom, A.F.; Moses, H.L.; Mechanism of activation of latent recombinant transforming growth factor beta 1 by plasmin, J. Cell Biol., 1990, 110, 1361-1367
67. Sheppard, D. Integrin-mediated activation of latent transforming growth factor beta. Cancer Metastasis Rev., 2005, 24, 395-402.
68. Asano, Y.; Ihn, H.; Yamane, K.; Jinnin, M.; Mimura, Y.; Tamaki, K. Increased expression of integrin alpha(v)beta3 contributes to the establishment of autocrine TGF-beta signaling in scleroderma fibroblasts, J. Immunol., 175, 2005, 7708-7718.
69. Asano, Y.; Ihn, H.; Yamane, K.; Jinnin, M.; Mimura, Y.; Tamaki, K. Involvement of alphavbeta5 integrin-mediated activation of la tent transforming growth factor beta1 in autocrine transforming growth factor beta signaling in systemic sclerosis fibroblasts. Arthritis Rheum., 2005, 52, 2897-2905
70. Munger, J.S.; Huang, X.; Kawakatsu, H.; Griffiths, M.J.; Dalton, S.L.; Wu, J.; Pittet, J.F.; Kaminski, N.; Garat, C.; Matthay, M.A.; Rifkin, D.B.; Sheppard, D. The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis, Cell, 1999, 96, 319-328.
71. Asano, Y.; Ihn, H.; Yamane, K.; Jinnin, M.; Tamaki, K. Increased expression of integrin alphavbeta5 induces the myofibroblastic differentiation of dermal fibroblasts. Am. J. Pathol., 2006, 168, 499-510
72. Wipff, P.J.; Rifkin, D.B.; Meister J.J.; Hinz, B. Myofibroblast contraction activates TGF β 1 from the extracellular matrix. J. Cell Biol., 2007, 179, 1311-1323.
73. Turner, C.E. Paxillin and focal adhesion signaling. Nat. Cell Biol., 2000, 2, E231-E236.
74. Ishibe, S.; Joly, D.; Liu, Z.X.; Cantley, L.G. Paxillin serves as an ERK-regulated scaffold for coordinating FAK and Rac activation in epithelial morphogenesis. Mol. Cell., 2004, 6, 257-267.
75. Banyard, J.; Anand-Apte, B.; Symons, M.; Zetter, B.R. Motility and invasion are differentially modulated by Rho family GTPases. Oncogene, 2000, 19, 580-591.
76. Nobes, C.D.; Hall, A. Rho GTPases control polarity, protrusion, and adhesion during cell movement. J. Cell Biol., 1999, 144, 1235-1244.
77. Liu, S.; Kapoor, M.; Leask, A. Rac1 expression by fibroblasts is required for tissue repair in vivo. Am. J. Pathol., 2009, 174, 1847-1856.
78. Liu, S.; Kapoor, M.; Shi-wen, X.; Kennedy, L.; Denton, C.P.; Glogauer, M.; Abraham, D.J.; Leask, A. Investigation of the role of Rac1 in a bleomycin-induced scleroderma model using fibroblastspecific Rac1 knockout mice. Arthritis Rheum., 2008, 58, 2189-2195.
79. Minakami, R.; Sumimotoa, H. Phagocytosis-coupled activation of the superoxide-producing phagocyte oxidase, a member of the NADPH oxidase (nox) family. Int. J. Hematol., 2006, 84, 193-198.
80. Ueyama, T.; Geiszt, M.; Leto, T.L. Involvement of Rac1 in activation of multicomponent Nox1- and Nox3-based NADPH oxidases. Mol. Cell Biol., 2006, 26, 2160-2174.
81. Shi-wen, X.; Liu, S.; Sonylal, S.; Denton, C.P.; Abraham, D.J.; Leask, A. Rac inhibition reverses the phenotype of fibrotic fibroblasts. PLOS ONE, 2009, 4, e7438.
82. Clerkin, J.S.; Naughton, R.; Quiney, C.; Cotter, T.G. Mechanisms of ROS modulated cell survival during carcinogenesis. Cancer Lett., 2008, 266, 30-36.
83. Prekeris, R.; Hernandez, R.M.; Mayhew, M.W.; White, M.K.; Terrian, D.M. Molecular analysis of the interactions between protein kinase C-epsilon and filamentous actin. J. Biol. Chem., 1998, 273, 26790-26798.
84. Bogatkevich, G.S.; Tourkina, E.; Abrams, C.S.; Harley, R.A.; Silver, R.M.; Ludwicka-Bradley, A. Contractile activity and smooth muscle alpha-actin organization in thrombin-induced human lung myofibroblasts. Am. J. Physiol. Lung Cell Mol. Physiol., 2003, 285, L334-L343.
85. Leask, A.; Shi-wen, X.; Chen, Y.; Khan, K.; Eastwood, M.; Black, C.M.; Abraham, D.J. Protein kinase C ε is required for cutaneous wound closure and myofibroblast formation. J. Cell Sci., 2008, 121, 3459-3467.
86. Ondrey, F. Peroxisome proliferator-activated receptor gamma pathway targeting in carcinogenesis: implications for chemoprevention. Clin. Cancer Res., 2009, 15(1), 2-8.
87. Gills, J.J.; Dennis, P.A. Perifosine: update on a novel Akt inhibitor. Curr. Oncol. Rep., 2009, 11(2), 102-110.
88. Nassar, N.; Cancelas, J.; Zheng, J.; Williams, D.A.; Zheng, Y. Structure-function based design of small molecule inhibitors targeting Rho family GTPases. Curr. Top. Med. Chem., 2006, 6(11), 1109-1116.
89. Adenis, A.; Penel, N.; Blay, J.Y. Imatinib in gastrointestinal stromal tumor: does treatment duration matter? Oncology, 2009, 77, 157-161.